{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:19:09Z","timestamp":1790605149695,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.euroneuro.2020.12.006","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T15:23:20Z","timestamp":1609601000000},"page":"92-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder"],"prefix":"10.1016","volume":"43","author":[{"given":"E.","family":"Sherwood Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"McArdle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayme","family":"Palka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collette","family":"Bice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ivleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markey","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Tipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2020.12.006_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hup.908","article-title":"Factors associated with treatment nonadherence among US bipolar disorder patients","volume":"23","author":"Baldessarini","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0002","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1023\/A:1022486705184","article-title":"The central 5-HT3 receptor in CNS disorders","volume":"23","author":"Bloom","year":"1998","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0003","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1530-0277.2009.01024.x","article-title":"A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence","volume":"33","author":"Brown","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0004","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4088\/JCP.v69n0502","article-title":"A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders","volume":"69","author":"Brown","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0165-0327(00)00169-5","article-title":"Drug abuse and bipolar disorder: comorbidity or misdiagnosis?","volume":"65","author":"Brown","year":"2001","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0006","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0007","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1176\/ajp.1979.136.4b.583","article-title":"Bipolar illness: factors in drinking behavior","volume":"136","author":"Dunner","year":"1979","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0008","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/187152708786927886","article-title":"The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy","volume":"7","author":"Engleman","year":"2008","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40345-018-0133-9","article-title":"Antidepressants in bipolar depression: an enduring controversy","volume":"6","author":"Gitlin","year":"2018","journal-title":"Int. J. Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.4088\/JCP.v60n1103","article-title":"A history of substance abuse complicates remission from acute mania in bipolar disorder","volume":"60","author":"Goldberg","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pbb.2014.05.024","article-title":"5HT3 receptor antagonist (ondansetron) reverses depressive behavior evoked by chronic unpredictable stress in mice: modulation of hypothalamic-pituitary-adrenocortical and brain serotonergic system","volume":"124","author":"Gupta","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.steroids.2015.01.021","article-title":"Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-like behavior and oxidative stress in mice","volume":"96","author":"Gupta","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2014.04.008","article-title":"Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models","volume":"735","author":"Gupta","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0014","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1176\/ajp.152.6.856","article-title":"Predicting the ``revolving door'' phenomenon among patients with schizophrenic, schizoaffective, and affective disorders","volume":"152","author":"Haywood","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0015","first-page":"613","article-title":"Sources of lithium resistance in mixed mania","volume":"22","author":"Himmelhoch","year":"1986","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0016","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/01.ALC.0000095635.46911.5D","article-title":"Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals","volume":"27","author":"Johnson","year":"2003","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0018","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1037\/h0080151","article-title":"The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization","volume":"66","author":"Kessler","year":"1996","journal-title":"Am. J. Orthopsychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0020","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/330746a0","article-title":"Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding","volume":"330","author":"Kilpatrick","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0021","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1749-6632.1992.tb25966.x","article-title":"Neural mechanisms of drug reinforcement","volume":"654","author":"Koob","year":"1992","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0022","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1399-5618.2007.00467.x","article-title":"Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder","volume":"9","author":"Kupka","year":"2007","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0023","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.bbr.2013.09.002","article-title":"Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats","volume":"256","author":"Li","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0024","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1152\/jn.1991.66.4.1329","article-title":"Inhibition of 5-HT3 receptor-mediated ion current by divalent metal cations in NCB-20 neuroblastoma cells","volume":"66","author":"Lovinger","year":"1991","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0197-0186(99)00054-6","article-title":"5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic","volume":"35","author":"Lovinger","year":"1999","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0026","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.4088\/JCP.v68n0802","article-title":"Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders","volume":"68","author":"Manwani","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0027","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1192\/bjp.120.558.523","article-title":"Manic-depressive illness: a comparative study of patients with and without a family history","volume":"120","author":"Mendlewicz","year":"1972","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0028","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0029","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1176\/ajp.131.10.1130","article-title":"Bipolar affective disorder and alcoholism","volume":"131","author":"Morrison","year":"1974","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40263-017-0449-5","article-title":"Pharmacological Treatment of bipolar disorder with comorbid alcohol use disorder","volume":"31","author":"Naglich","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0031","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1192\/bjp.159.1.123","article-title":"Outcome of bipolar disorder on long-term treatment with lithium","volume":"159","author":"O'Connell","year":"1991","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0032","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4088\/JCP.09m05514yel","article-title":"Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study","volume":"71","author":"Perlis","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0033","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gut.2004.055251","article-title":"Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study","volume":"54","author":"Piche","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0034","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/FBP.0b013e3282f3cfd4","article-title":"Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models","volume":"19","author":"Ramamoorthy","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0035","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0036","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.comppsych.2008.06.008","article-title":"Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic","volume":"50","author":"Sajatovic","year":"2009","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0037","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/00952990.2017.1292279","article-title":"Management of comorbid bipolar disorder and substance use disorders","volume":"43","author":"Salloum","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0038","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archpsyc.62.1.37","article-title":"Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study","volume":"62","author":"Salloum","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0039","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1521-0391.1994.tb00246.x","article-title":"Using the general behavior inventory to screen for mood disorders among patients with psychoactive substance dependence","volume":"3","author":"Saxon","year":"1994","journal-title":"Am. J. Addict."},{"issue":"1","key":"10.1016\/j.euroneuro.2020.12.006_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00132576-200205000-00004","article-title":"Cognitive\u2013behavioral treatment of bipolar disorder and substance abuse: a preliminary randomized study","volume":"1","author":"Schmitz","year":"2002","journal-title":"Addict. Disord. Treat."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0041","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1192\/bjp.172.4.345","article-title":"Substance misuse and risk of aggression and offending among the severely mentally ill","volume":"172","author":"Scott","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0042","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-3-642-28720-6_170","article-title":"Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points","volume":"13","author":"Soderpalm","year":"2011","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0043","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00005053-199406000-00007","article-title":"Substance abuse and bipolar affective disorder","volume":"182","author":"Sonne","year":"1994","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0044","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/ajad.12346","article-title":"A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder","volume":"25","author":"Sylvia","year":"2016","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0045","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archpsyc.1996.01830090023004","article-title":"A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia","volume":"53","author":"Thase","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0046","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archpsyc.1990.01810240026005","article-title":"Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis","volume":"47","author":"Tohen","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0047","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1399-5618.2011.00973.x","article-title":"A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report","volume":"14","author":"Tolliver","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0048","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/ADT.0b013e31821e1072","article-title":"Changes in affect and drinking outcomes in a pharmacobehavioral trial for alcohol dependence","volume":"11","author":"Vaughan","year":"2012","journal-title":"Addict Disord Their Treat"},{"issue":"1","key":"10.1016\/j.euroneuro.2020.12.006_bib0049","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1176\/ajp.2007.164.1.100","article-title":"A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence","volume":"164","author":"Weiss","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1037\/0033-295X.94.4.469","article-title":"A psychomotor stimulant theory of addiction","volume":"94","author":"Wise","year":"1987","journal-title":"Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2020.12.006_bib0051","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0022-3565(25)20657-7","article-title":"Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells","volume":"278","author":"Zhou","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20309871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20309871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:59:02Z","timestamp":1760378342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X20309871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":51,"alternative-id":["S0924977X20309871"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.12.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}